Coherus BioSciences Inc (CHRS) - Total Liabilities
Based on the latest financial reports, Coherus BioSciences Inc (CHRS) has total liabilities worth $197.33 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Coherus BioSciences Inc equity growth rate to track the company's year-over-year net asset growth rate.
Coherus BioSciences Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Coherus BioSciences Inc's total liabilities have evolved over time, based on quarterly financial data. See Coherus BioSciences Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Coherus BioSciences Inc Competitors by Total Liabilities
The table below lists competitors of Coherus BioSciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gunung Raja Paksi
JK:GGRP
|
Indonesia | Rp71.17 Million |
|
ST George Mining Ltd
AU:SGQ
|
Australia | AU$3.54 Million |
|
Caisse Régionale de Crédit Agricole du Morbihan
PA:CMO
|
France | €11.62 Billion |
|
Saniona AB
ST:SANION
|
Sweden | Skr44.58 Million |
|
Smart Parking Ltd
AU:SPZ
|
Australia | AU$42.15 Million |
|
Sichuan Dowell Science and Technology Inc
SHE:300535
|
China | CN¥459.22 Million |
|
Liaoning Kelong Fine ChemicalInc
SHE:300405
|
China | CN¥602.86 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Coherus BioSciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Coherus BioSciences Inc (CHRS) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Coherus BioSciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Coherus BioSciences Inc (2012–2025)
The table below shows the annual total liabilities of Coherus BioSciences Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $197.33 Million | -66.01% |
| 2024-12-31 | $580.52 Million | -29.47% |
| 2023-12-31 | $823.03 Million | +33.12% |
| 2022-12-31 | $618.26 Million | +6.30% |
| 2021-12-31 | $581.61 Million | +3.73% |
| 2020-12-31 | $560.67 Million | +84.61% |
| 2019-12-31 | $303.71 Million | +119.99% |
| 2018-12-31 | $138.06 Million | +4.53% |
| 2017-12-31 | $132.08 Million | -17.00% |
| 2016-12-31 | $159.13 Million | -27.44% |
| 2015-12-31 | $219.31 Million | +82.06% |
| 2014-12-31 | $120.46 Million | +34.10% |
| 2013-12-31 | $89.83 Million | +418.02% |
| 2012-12-31 | $17.34 Million | -- |
About Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin… Read more